This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thomas, M. A. Articles by Wold, W. S.M. Search for Related Content PubMed PubMed Citation Articles by Thomas, M. A. Articles by Wold, W. S.M.

Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus Vectors

¹ Molecular Microbiology and Immunology, Saint Louis University School of Medicine and ² Division of Comparative Medicine, Washington University School of Medicine, St. Louis, Missouri

Requests for reprints: William S.M. Wold, Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1402 South Grand Boulevard, St. Louis, MO 63104. Phone: 314-977-8857; Fax: 314-977-8717; E-mail: woldws{at}slu.edu.

Oncolytic adenoviruses represent an innovative approach to cancer therapy. These vectors are typically evaluated in immunodeficient mice with human xenograft tumors. However, in addition to being immunodeficient, this model is limited because normal and cancerous mouse tissues are poorly permissive for human adenovirus replication. This prompted us to search for a model that more accurately reflects the use of oncolytic adenoviruses in cancer patients. To this end, we developed a novel Syrian hamster model that is both immunocompetent and replication-permissive. We found that human adenovirus replicates well in Syrian hamster cell lines and confirmed replication in the lungs. Oncolytic adenovirus injection showed efficacy in three different hamster tumor models. Furthermore, i.t. oncolytic adenovirus injection resulted in suppression of primary and metastatic lesions, i.t. replication and necrosis, vector entrance into the bloodstream, replication in the liver and lungs, and anti-adenovirus antibody induction. Our findings show that the Syrian hamster is a promising immunocompetent model that is permissive to human adenovirus replication in tumors as well as normal tissues. Therefore, the Syrian hamster model may become a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and efficacy can be evaluated. (Cancer Res 2006; 66(3): 1270-6)

This article has been cited by other articles:

				K. Matthews, P. E. Noker, B. Tian, S. D. Grimes, R. Fulton, K. Schweikart, R. Harris, R. Aurigemma, M. Wang, M. N. Barnes, et al. Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4131 - 4137. [Abstract] [Full Text] [PDF]

				M. Robinson, B. Li, Y. Ge, D. Ko, S. Yendluri, T. Harding, M. VanRoey, K. R. Spindler, and K. Jooss Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors J. Virol., April 15, 2009; 83(8): 3450 - 3462. [Abstract] [Full Text] [PDF]

				D. Dhar, J. F. Spencer, K. Toth, and W. S. M. Wold Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters J. Virol., March 1, 2009; 83(5): 2130 - 2139. [Abstract] [Full Text] [PDF]

				W. C. Russell Adenoviruses: update on structure and function J. Gen. Virol., January 1, 2009; 90(1): 1 - 20. [Abstract] [Full Text] [PDF]

				A. Ketola, A. Hinkkanen, F. Yongabi, P. Furu, A.-M. Maatta, T. Liimatainen, R. Pirinen, M. Bjorn, T. Hakkarainen, K. Makinen, et al. Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable Osteosarcoma Cancer Res., October 15, 2008; 68(20): 8342 - 8350. [Abstract] [Full Text] [PDF]

				K. Toth, J. F. Spencer, D. Dhar, J. E. Sagartz, R. M. L. Buller, G. R. Painter, and W. S. M. Wold Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model PNAS, May 20, 2008; 105(20): 7293 - 7297. [Abstract] [Full Text] [PDF]

				D. Sarkar, I. V. Lebedeva, Z.-z. Su, E.-S. Park, L. Chatman, N. Vozhilla, P. Dent, D. T. Curiel, and P. B. Fisher Eradication of Therapy-Resistant Human Prostate Tumors Using a Cancer Terminator Virus Cancer Res., June 1, 2007; 67(11): 5434 - 5442. [Abstract] [Full Text] [PDF]

				M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al. E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050. [Abstract] [Full Text] [PDF]